Generations of Tradition Meet 26 Years of Modern Science

Crinum latifolium L has over 100 years of history for safe use supporting both men’s prostate health and women’s hormonal balance. From traditional herbalists, to royal kings and queens, the rare herb was coveted for longevity, virility and immune support. Today, we draw solid conclusions from the research of internationally award-winning Vietnamese pharmacologist Dr. Nguyen Thi Ngoc Tram & her collaboration with European and American scientists.*

Only Dr. Tram’s proprietary Crinum plants, developed and researched since 1990 - Crinum latifolium L var. crilae Tram & Khanh - have been the subject of published clinical studies, and only Crila Health is licensed to use the standardized extract from this nutrient in our supplements. There's only 1 Crila®. You only have 1 prostate. Willing to risk it?

Research Listings

Clinical Trial, Evaluating Crila® for Prostate Health

Assessment of Crila® extract from Crinum latifolium for Prostate Health. Dr. Tram D T, Vietnam National Institute of Gerontology, Ministry of Health of Vietnam, 2005.

Three hospitals in Vietnam studied 157 men in a study evaluating the possible benefits of Crila® for prostate health, as well as support for urinary regularity. Within two weeks, 140 men noticed the beneficial effect of Crila® with the maximum benefit reached in eight weeks. The study concluded 89.18 percent of the men in the study had good or very good results with Crila®. A small number of men suffered mild side effects - abdominal distension, dizziness, and insomnia. In 2005, the Ministry of Health approved the use of Crila® throughout Vietnam for men seeking natural support for prostate health.*

Clinical Trial, Evaluating Crila® for Uterine Health

Evaluate the effect of Crila® extract for uterine health. Dr. Hoa, V T, National Hospital of Gynecology and Obstetrics, Ministry of Health of Vietnam. 2007.

In 2007, a three-month study of 195 women to examine the effects of Crila® for uterine health was conducted in three hospitals in Vietnam. Researchers found that Crila® promoted uterine health in 79.5 percent of the women. Additionally, 36 percent of the women who had expressed (at study start) that they had a wellness goal of supporting healthy menstrual flow, experienced support for that goal after a 90-day course of Crila®.*

Side effects reported were slight, and included nausea, headache, vaginal dryness, and hot flashes. These minimal side effects decreased with time, and medical intervention was not necessary. For example, 15 percent experienced mild nausea at the end of the first 30 days, but this number dropped to 5 percent at the end of 90 days. In 2007, the Ministry of Health approved the use of the Crila® for Menopause / Crila® for Uterine Health formula for women throughout Vietnam.

American Research Examining Crila® for the Estrogenicity of Crinum latifolium L var. crilae Tram & Khanh (Amaryllidaceae) Using Cell-based and Receptor-based Assays

Examining the estrogenicity of Crinum latifolium L. var.crilae Tram and Khanh, var n. AmaryIlidaceae) using cell-based and receptor-based assays. Poster Session North American Menopause Society Washington D.C. 2014. Menopause 2014;21(12): 1335

In 2013-2014, scientists at UIC under NIH grant number P50 AT000155 from the Office of Dietary Supplements and the National Center for Complementary and Alternative Medicine, employed a combination of receptor-based and cell-based assays to determine the presence of estrogenic compounds in an extract of C. latifolium which was obtained from Crila Health. For receptor-based screening, recombinant human ER alpha and ER beta was incubated with C. latifolium extract and bound ligands were detected using pulsed ultrafiltration liquid chromatography - mass spectrometry....Ishikawa human endometrial adenocarcinoma cells that expressed estrogen-inducible alkaline phosphatase were used to determine if the extract had estrogenic or anti-estrogenic properties....

Conclusion: The fact that the cell-based assay indicated no estrogenic or anti-estrogenic activity for C. latifolium indicates that this botanical is probably not estrogenic in vivo. Therefore, there should be no concern that C. latifolium might have undesirable estrogenic consequences...

Results were presented by T Burton in the Poster Abstract session, NAMS North American Menopause Society annual conference, Washington, DC. October 2014. Summary text of the Abstract can be found at http://www.menopause.org/ under the 2014 Meeting / Abstracts.

European Research on Crinum latifolium for prostate health*

An article on pre-clinical study of Crila® Crinum latifolium L extract conducted at the Innsbruck Medical University to research aspects of prostate health. Jenny M, Wondrak A, Zvetkova E, Tram NT, Phi PT, Schennach H, Culig Z, Ueberall F, Fuchs D. Sci Pharm. 2011 Jun;79(2):323-35. doi: 10.3797/scipharm.1011-13. Epub 2011 Apr 5.

Results of the specific Crila® Crinum latifolium extraction found potent in vitro antioxidant activity measured with an antioxidant ORAC value of 1610; significant immune response and cellular health effects of the extract were shown, and believed to support prostate health; cell study indicated immune health support and possible beneficial effects for prostate health at the cellular level.

Crila® Editor's Note: the Crinum extraction in this research study differs from the commercial extraction sold as Crila® although both come from the same cultivar of Crinum latifolium L var. crilae Tram & Khanh. As with all laboratory research, well-designed clinical trials are necessary before doctors can evaluate the safety and efficacy of the laboratory premise in human subjects.

Research on Pharmacology and Toxicity of Crila®

Research and results of toxicity studies, 2002, 2003, and 2004 concluding the safe use of Crila®. Dao, VP, Ministry of Health of Vietnam, 2004. Good Agriculture & Collection Practices for new variety Crinum latifolium L. var. crilae Tram & Khanh enables the first commercial scale production of this Vietnamese traditional medicinal herb. Planta Med 2012; 78 - P13. DOI: 10.1055/s-0032-1307521

CS McKinney, NTN Tram. Congress Abstract.

In 1990, pharmacologist Nguyen T.N. Tram began the first scientific study of the Vietnamese plant Crinum latifolium L to determine if claims from Vietnamese traditional health were wishful folklore or efficacious fact. Her investigations sought to substantiate Crinum's traditional use for male and female reproductive wellness. Her proprietary Crinum extraction was used in clinical trials studying prostate and uterine health. Tram created capacity for scalable commercial production via strictly controlled authentication, and modern practices to ensure safety and quality in a closed vertical process from plantation to factory to consumer.*

Research on Crila® at the Bulgarian Academy of Sciences

Local (in situ) influence of Crila® conducted in laboratory research.
Bankov I., Toshkova R., Zvetkova E. Experimental Pathology and Parisitology, Bulgarian Academy of Sciences, 2009.

A Review of Crinum latifolium (Amaryllidaceae).

Nguyen Thi Ngoc Tram, Titorenkova T V, St. Bankova V, Handjieva N V, Popov S S. Vietnam Pharmaceutical Corporation, Laboratory for Chemistry and Technology of Natural Substances. Elsevier. Fitoterapia, 2002 June; 73(3):183-208.

GC-MS of Crinum latifolium L. alkaloids

Tram N T, Mitova M, Bankova V, Handjieva N, Popov S S, Vietnam Pharmaceutical Corporation, Laboratory for chemistry and Technology of Natural Substances, Zeitschrift für Naturforschung C. 2002 Mar-Apr;57(3-4):239-42.

Study of properties in human peripheral blood mononuclear cells

Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis were studied in human peripheral blood mononuclear cells. Zvetkova E, Wirleitner B, Tram NT, Schennach H, Fuchs D. Institute of Experimental Morphology and Anthropology. Bulgarian Academy of Sciences. International Immunopharmacology. 2001 Nov;1(12):2143-50.

Crinum species in traditional and modern usage. Fennell CW, van Staden J. Journal of Ethnopharmacology. 2001 Nov; 78 (1): 15-26. Abstract: Crinums are large, showy plants with umbels of lily-like flowers. They are found in tropical and subtropical regions throughout the world, where, for centuries, they have been used in traditional medicine. Phytochemical analysis has recently yielded a vast array of compounds, including more than 150 different alkaloids. These are of the Amaryllidaceae type, with several noted effects. Even though much has been reported on the medicinal properties of Crinum, only an estimated 20 percent of the species worldwide are represented in these analyses, as reviewed in this paper.

Pre-clinical research on Vietnamese Crinum latifolium L

Pre-clinical laboratory research on the action of cold-hot aqueous extracts (decoctions) from Vietnamese plant Crinum latifolium (L). Tram Ng., Yanchev I., Zvetkova E., Dineva J., Katzarova E., Kostov G., Svilenov D., Ilieva I., Schalamanov P. Experimental Pathology and Parasitology, 4/7, 2001, 9-12.

In Vitro T-lymphocyte activity in Vietnamese Crinum latifolium L

A novel in vitro T-lymphocyte activating factor in Vietnamese Crinum latifolium (L). Tram Ng Th Ng., Zvetkova E., Nikolova E., Katzarova E., Kostov G., Yanchev I., Baicheva O. Experimental Pathology and Parasitology, 3/1, 1999, 21-26.

NOTE: It is important to note that key clinical and pre-clinical research cited above was conducted utilizing extractions from the specific cultivar Crinum latifolium L var. crilae Tram & Khanh, developed, cultivated and processed by Dr. Nguyen Thi Ngoc Tram; and provided by either Dr. Tram or Crila Health. Reference to our research made by companies whose products contain other varities of Crinum latifolium L may be invalid and subject to legal action under the Lanham Act intended to protect consumers from false or misleading advertising.

As with all laboratory research, well-designed clinical trials are necessary before doctors can evaluate the safety and efficacy of the premise for human subjects.

Dr. Tram and Crila Health welcome inquiries for potential research collaboration from established North American doctors or scientists on a variety of aspects relating to prostate, menopause or uterine health. RFPs for World Bank funding, due in Spring 2015, address protocols for clinical trials on an aspect of prostate health and lung health. Inquiries may be sent to info@crilahealth.com.

Be a Wise Supplement Shopper

Trust Brands with Reliable Safety Studies

Some competitors refer to Dr Tram’s studies but use a different Crinum variety which, according to our testing, contain none of the key alkaloids in Crila®. Some of these products do contain alkaloids, commonly present in other Crinum varieties, that are actually detrimental to male sexual health. Only Crila Health products contain Dr Tram’s clinically studied proprietary Crinum cultivar, in a concentrated extract, standardized to ensure consistent potency and results, and formulated to meet California Prop 65 standards of safety. Grown only on the doctor’s plantations, this “farm to table” integration assures no adulteration from detrimental “look-alike” plant varieties. Safety studies commissioned by Crila Health include the Estrogen Free research conducted at the University of Illinois, College of Pharmacy. Individual batch testing is conducted in compliance with FDA regulations; further testing by independent American laboratories assures consumer safety.

There's only 1 Crila®.
You have only 1 prostate.